Fundamental Analysis of CEL-SCI CORP(NYSEARCA:CVM) stock

Fundamental Rating

We assign a fundamental rating of 1 out of 10 to CVM. CVM was compared to 577 industry peers in the Biotechnology industry. Both the profitability and financial health of CVM have multiple concerns. CVM does not seem to be growing, but still is valued expensively.

Quickly go to:

1. Profitability

1.1 Basic Checks

In the past year CVM has reported negative net income.

CVM had a negative operating cash flow in the past year.

CVM had negative earnings in each of the past 5 years.

In the past 5 years CVM always reported negative operating cash flow.

1.2 Ratios

The Return On Assets of CVM (-99.68%) is worse than 78.22% of its industry peers.

CVM has a Return On Equity of -209.39%. This is in the lower half of the industry: CVM underperforms 71.25% of its industry peers.

		Industry Rank	Sector Rank
ROA	-99.68%
ROE	-209.39%
ROIC	N/A

ROA(3y)-76.3%

ROA(5y)-76.74%

ROE(3y)-142.28%

ROE(5y)-202.3%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for CVM so they could not be analyzed.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	N/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

Compared to 1 year ago, CVM has more shares outstanding

The number of shares outstanding for CVM has been increased compared to 5 years ago.

Compared to 1 year ago, CVM has a worse debt to assets ratio.

2.2 Solvency

CVM has an Altman-Z score of -23.92. This is a bad value and indicates that CVM is not financially healthy and even has some risk of bankruptcy.

Looking at the Altman-Z score, with a value of -23.92, CVM is doing worse than 90.42% of the companies in the same industry.

CVM has a Debt/Equity ratio of 0.63. This is a neutral value indicating CVM is somewhat dependend on debt financing.

CVM has a Debt to Equity ratio of 0.63. This is in the lower half of the industry: CVM underperforms 74.74% of its industry peers.

		Industry Rank	Sector Rank
Debt/Equity	0.63
Debt/FCF	N/A
Altman-Z	-23.92

ROIC/WACCN/A

WACCN/A

2.3 Liquidity

CVM has a Current Ratio of 1.67. This is a normal value and indicates that CVM is financially healthy and should not expect problems in meeting its short term obligations.

Looking at the Current ratio, with a value of 1.67, CVM is doing worse than 80.66% of the companies in the same industry.

CVM has a Quick Ratio of 1.18. This is a normal value and indicates that CVM is financially healthy and should not expect problems in meeting its short term obligations.

With a Quick ratio value of 1.18, CVM is not doing good in the industry: 84.67% of the companies in the same industry are doing better.

		Industry Rank	Sector Rank
Current Ratio	1.67
Quick Ratio	1.18

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

CVM shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 22.79%, which is quite impressive.

EPS 1Y (TTM)22.79%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%26.32%

Revenue 1Y (TTM)N/A

Revenue growth 3YN/A

Revenue growth 5YN/A

Sales Q2Q%N/A

3.2 Future

CVM is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 25.81% yearly.

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

EPS Next Y-1.84%

EPS Next 2Y14.22%

EPS Next 3Y18.47%

EPS Next 5Y25.81%

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for CVM. In the last year negative earnings were reported.

Also next year CVM is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

CVM's earnings are expected to grow with 18.47% in the coming years. This may justify a more expensive valuation.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y14.22%

EPS Next 3Y18.47%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

CVM does not give a dividend.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

CEL-SCI CORP

NYSEARCA:CVM (7/26/2024, 7:24:09 PM)

After market: 1.19 -0.12 (-9.16%)

1.31

+0.1 (+8.26%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)

Earnings (Next)

Inst Owners

Inst Owner Change

Ins Owners

Ins Owner Change

Market Cap70.95M

Analysts

Price Target

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Dividend Growth(5Y)

Div Incr Years

Div Non Decr Years

Ex-Date

Surprises & Revisions

EPS beat(2)

Avg EPS beat(2)

Min EPS beat(2)

Max EPS beat(2)

EPS beat(4)

Avg EPS beat(4)

Min EPS beat(4)

Max EPS beat(4)

EPS beat(8)

Avg EPS beat(8)

EPS beat(12)

Avg EPS beat(12)

EPS beat(16)

Avg EPS beat(16)

Revenue beat(2)

Avg Revenue beat(2)

Min Revenue beat(2)

Max Revenue beat(2)

Revenue beat(4)

Avg Revenue beat(4)

Min Revenue beat(4)

Max Revenue beat(4)

Revenue beat(8)

Avg Revenue beat(8)

Revenue beat(12)

Avg Revenue beat(12)

Revenue beat(16)

Avg Revenue beat(16)

PT rev (1m)

PT rev (3m)

EPS NQ rev (1m)

EPS NQ rev (3m)

EPS NY rev (1m)

EPS NY rev (3m)

Revenue NQ rev (1m)

Revenue NQ rev (3m)

Revenue NY rev (1m)

Revenue NY rev (3m)

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA

EPS(TTM)

EPS(NY)

Fwd EY

FCF(TTM)

FCFY

OCF(TTM)

OCFY

SpS

BVpS

TBVpS

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-99.68%
ROE	-209.39%
ROCE
ROIC
ROICexc
ROICexgc
OM	N/A
PM (TTM)	N/A
GM	N/A
FCFM

ROA(3y)

ROA(5y)

ROE(3y)

ROE(5y)

ROIC(3y)

ROIC(5y)

ROICexc(3y)

ROICexc(5y)

ROICexgc(3y)

ROICexgc(5y)

ROCE(3y)

ROCE(5y)

ROICexcg growth 3Y

ROICexcg growth 5Y

ROICexc growth 3Y

ROICexc growth 5Y

OM growth 3Y

OM growth 5Y

PM growth 3Y

PM growth 5Y

GM growth 3Y

GM growth 5Y

F-Score

Asset Turnover0

Health

		Industry Rank	Sector Rank
Debt/Equity	0.63
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio	1.67
Quick Ratio	1.18
Altman-Z

F-Score

WACC

ROIC/WACC

Cap/Depr(3y)

Cap/Depr(5y)

Cap/Sales(3y)

Cap/Sales(5y)

Profit Quality(3y)

Profit Quality(5y)

High Growth Momentum

Growth

EPS 1Y (TTM)22.79%

EPS 3YN/A

EPS 5Y

EPS Q2Q%

EPS Next Y-1.84%

EPS Next 2Y

EPS Next 3Y

EPS Next 5Y

Revenue 1Y (TTM)N/A

Revenue growth 3YN/A

Revenue growth 5Y

Sales Q2Q%

Revenue Next Year

Revenue Next 2Y

Revenue Next 3Y

Revenue Next 5Y

EBIT growth 1Y

EBIT growth 3Y

EBIT growth 5Y

EBIT Next Year

EBIT Next 3Y

EBIT Next 5Y

FCF growth 1Y

FCF growth 3Y

FCF growth 5Y

OCF growth 1Y

OCF growth 3Y

OCF growth 5Y

CEL-SCI CORP (CVM)

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens